Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Free Cash Flow (2016 - 2025)

Tg Therapeutics has reported Free Cash Flow over the past 10 years, most recently at $19.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $19.6 million for Q4 2025, up 176.35% from a year ago — trailing twelve months through Dec 2025 was -$25.0 million (up 38.4% YoY), and the annual figure for FY2025 was -$25.0 million, up 38.4%.
  • Free Cash Flow for Q4 2025 was $19.6 million at Tg Therapeutics, up from -$23.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TGTX hit a ceiling of $83.7 million in Q3 2023 and a floor of -$87.0 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$27.2 million (2024), compared with a mean of -$28.5 million.
  • Biggest five-year swings in Free Cash Flow: surged 342.63% in 2023 and later crashed 250.19% in 2025.
  • Tg Therapeutics' Free Cash Flow stood at -$87.0 million in 2021, then surged by 72.56% to -$23.9 million in 2022, then skyrocketed by 44.67% to -$13.2 million in 2023, then plummeted by 94.26% to -$25.7 million in 2024, then soared by 176.35% to $19.6 million in 2025.
  • The last three reported values for Free Cash Flow were $19.6 million (Q4 2025), -$23.2 million (Q3 2025), and $7.4 million (Q2 2025) per Business Quant data.